GlassScriptPhysician profile
Elena Katz
NPI 1902047947
$7,723.26
in general payments reported to CMS, 2019-2025
43 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $1,559 · 2021: $2,328 · 2022: $2,014 · 2023: $15.03 · 2024: $38.34 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $662.30 | 2019-2022 | |
| Janssen Biotech, INC. | $597.83 | 2019-2022 | |
| Amgen INC. | $594.17 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $510.73 | 2019-2022 | |
| Genzyme Corporation | $412.12 | 2019-2022 | |
| Lilly USA, LLC | $412.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $395.02 | 2019-2022 | |
| Taiho Oncology, INC. | $357.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $326.07 | 2020-2025 | Nucala, Jemperli, Zejula |
| E.R. Squibb & Sons, L.L.C. | $312.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $279.56 | 2019-2025 | |
| Puma Biotechnology, INC. | $262.46 | 2019-2025 | |
| Array Biopharma INC | $261.18 | 2021-2022 | |
| Incyte Corporation | $242.40 | 2019-2022 | |
| Eisai INC. | $193.42 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.